Physician profile
Peter C Jansen
NPI 1689634172
$16,830.44
in general payments reported to CMS, 2019-2025
58 companies · $1,834 in 2025
The $1,834 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,472 · 2020: $2,371 · 2021: $3,347 · 2022: $3,131 · 2023: $1,916 · 2024: $1,758 · 2025: $1,834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,458 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,458.13 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,509.09 | 2019-2025 | |
| Novo Nordisk INC | $2,033.37 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals Lp | $1,937.33 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $1,239.35 | 2019-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $1,111.86 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $1,080.94 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $743.38 | 2019-2025 | Jardiance |
| Abbott Laboratories | $598.18 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astellas Pharma US INC | $571.93 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $563.72 | 2019-2025 | |
| Allergan, INC. | $526.42 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $326.22 | 2019-2025 | Dificid, Capvaxive, Gardasil 9 |
| Amarin Pharma, INC. | $322.48 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $310.13 | 2019-2024 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $278.59 | 2021-2025 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Jansen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.